Evidence map›Paper›PMID 39120584›Full record

ArticleThe Journal of cell biology2024

INPP4B promotes PDAC aggressiveness via PIKfyve and TRPML-1-mediated lysosomal exocytosis.

Golam T Saffi, Lydia To, Nicholas Kleine, Ché M P Melo, Keyue Chen, Gizem Genc, K C Daniel Lee, Jonathan Tak-Sum Chow, Gun Ho Jang, Steven Gallinger and 2 more

Abstract read
In one paragraph

Article in The Journal of cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Golam T SaffiDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0009-0007-3936-2489
Lydia ToDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0009-0008-4862-6826
Nicholas KleineDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0009-0001-1220-3599
Ché M P MeloDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0009-0007-2812-2498
Keyue ChenDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0000-0003-2349-2186
Gizem GencDepartment of Chemistry and Biology, Toronto Metropolitan University, Toronto, Canada.ORCID 0000-0003-3113-985X
K C Daniel LeeDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0009-0007-4045-6474
Jonathan Tak-Sum ChowDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0000-0002-6783-5032
Gun Ho JangPanCuRx Translational Research Initiative, Ontario Institute for Cancer Research , Toronto, Canada.ORCID 0000-0001-8169-7011
Steven GallingerPanCuRx Translational Research Initiative, Ontario Institute for Cancer Research , Toronto, Canada.ORCID 0000-0002-6998-9414
Roberto J BotelhoDepartment of Chemistry and Biology, Toronto Metropolitan University, Toronto, Canada.ORCID 0000-0002-7820-0999
Leonardo SalmenaDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.ORCID 0000-0003-4023-658X

Funding

Canada Foundation for Innovation CFI-33505Canada Research Chairs 950-23233Canadian Institute of Health Research CIHR487599Cancer Research Society PIN24261Human Frontier Career Development ProgramNatural Sciences and Engineering Council of Canada RGPIN-2020-04343Toronto Metropolitan UniversityUniversity of Toronto
6 · The paper itself

Abstract

Aggressive solid malignancies, including pancreatic ductal adenocarcinoma (PDAC), can exploit lysosomal exocytosis to modify the tumor microenvironment, enhance motility, and promote invasiveness. However, the molecular pathways through which lysosomal functions are co-opted in malignant cells remain poorly understood. In this study, we demonstrate that inositol polyphosphate 4-phosphatase, Type II (INPP4B) overexpression in PDAC is associated with PDAC progression. We show that INPP4B overexpression promotes peripheral dispersion and exocytosis of lysosomes resulting in increased migratory and invasive potential of PDAC cells. Mechanistically, INPP4B overexpression drives the generation of PtdIns(3,5)P2 on lysosomes in a PIKfyve-dependent manner, which directs TRPML-1 to trigger the release of calcium ions (Ca2+). Our findings offer a molecular understanding of the prognostic significance of INPP4B overexpression in PDAC through the discovery of a novel oncogenic signaling axis that orchestrates migratory and invasive properties of PDAC via the regulation of lysosomal phosphoinositide homeostasis.

Indexed as

Carcinoma, Pancreatic DuctalCell MovementExocytosisLysosomesNeoplasm InvasivenessPancreatic NeoplasmsPhosphatidylinositol 3-KinasesPhosphoric Monoester HydrolasesTransient Receptor Potential ChannelsAnimalsCalciumCell Line, TumorHumansMaleMicePhosphatidylinositol PhosphatesCalciumMCOLN1 protein, humanphosphatidylinositol-3,4-bisphosphate 4-phosphatasephosphatidylinositol 3,5-diphosphatePhosphatidylinositol 3-KinasesPhosphatidylinositol PhosphatesPhosphoric Monoester HydrolasesPIKFYVE protein, humanTransient Receptor Potential Channels

Identifiers

PMID39120584
PMCPMC11317760

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.